Drug maker Adcock Ingram has reported a double-digit increase in full-year earnings and dividends even as the seller of brands such as Corenza C and Panado navigated a weak economy that saw consumers coming under increasing pressure.
It described its results as a"healthy financial and operational performance" amid a weak economy characterised by currency weakness and volatility. It also noted that SA's cash-strapped consumers had also been constrained during the period.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: